Financial Data and Key Metrics Changes - In Q2 2025, IDEXX's revenue came in toward the midpoint of guidance, with organic sales increasing by 1% year over year [27][30] - Adjusted EBITDA margin declined by 40 basis points to 27.4%, reflecting gross margin performance and lower variable compensation expenses [28] - Free cash flow increased by 25% year over year to $147 million, representing 94% conversion versus adjusted net income [29] Business Line Data and Key Metrics Changes - In the Health and Science Technology (HST) segment, organic orders increased by 2% and organic sales increased by 4%, driven by positive pricing and volume increases in pharmaceuticals and data centers [30] - In the Fluid Management Technologies (FMT) segment, organic orders increased by 7%, but organic sales declined by 2% due to challenging prior year comparisons [31] - In the Fire and Safety Technologies (FST) segment, organic sales grew by 2%, but organic orders declined by 7% due to choppy order patterns [32] Market Data and Key Metrics Changes - Demand remained healthy in food and pharma applications, space and defense, and data center thermal management, while weaker areas included chemicals, automotive, and semiconductor lithography [10][11] - The company experienced a modest order recovery in July after a dynamic demand pattern in Q2, influenced by trade policy announcements [11][12] Company Strategy and Development Direction - IDEXX aims to extend growth potential through variable levels of integration to win in advantaged markets, focusing on cross-business collaboration and operational improvements [13][20] - The company is actively pursuing tuck-in acquisitions to scale and expand critical capabilities in advantaged markets, with a focus on maintaining a strong balance sheet and robust cash flow generation [37][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the quality of its businesses despite lowering back half financial projections due to slower decision-making and tariff-related uncertainties [12][34] - The company anticipates a stable baseline for orders moving forward, with a focus on leveraging operational capabilities to drive growth [50][76] Other Important Information - The company has updated its full-year organic sales growth guidance to approximately 1%, down from 1% to 3% previously, and adjusted adjusted EPS guidance to $7.85 to $7.95 [34] - IDEXX expects to fully mitigate tariff-related inflation through price increases and additional sourcing and supply chain savings [36] Q&A Session Summary Question: Can you discuss the delayed orders on the semiconductor side and the confidence in future orders? - Management noted that while there was oscillation in order patterns, July showed a recovery in both small and larger orders, providing confidence in future order fulfillment [46][48] Question: How much of the guidance cut is attributed specifically to Mott? - The guidance cut is primarily due to the MSS group and Mott, with frozen decision-making impacting revenue and profitability flow-through [92][93] Question: What is the current state of the life sciences segment? - The life sciences segment is experiencing a slow recovery, growing in low single digits, with some areas offsetting weaker segments [97] Question: Can you provide more detail on water performance in Q2? - Water performance was impacted by timing dynamics similar to other segments, but the business is expected to perform well going forward [104] Question: What is the strategic fit of the Microlam acquisition? - Microlam complements IDEXX's optical technologies business by providing precision optics, enhancing capabilities within the MSS platform [107][110]